Chromatine/Épigénétique
Les inhibiteurs de la chromatine/épigénétique sont des composés qui modulent la structure et la fonction de la chromatine ou interfèrent avec les modifications épigénétiques, telles que la méthylation de l'ADN et la modification des histones. Ces inhibiteurs sont des outils essentiels pour étudier la régulation de l'expression génique et le rôle de l'épigénétique dans des maladies telles que le cancer, les troubles neurologiques et les anomalies du développement. En ciblant les processus épigénétiques, ces inhibiteurs peuvent modifier les schémas d'expression génique et offrir de nouvelles perspectives thérapeutiques. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de la chromatine/épigénétique de haute qualité pour soutenir vos recherches en biologie moléculaire, génétique et épigénétique.
Sous-catégories appartenant à la catégorie "Chromatine/Épigénétique"
2242 produits trouvés pour "Chromatine/Épigénétique"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK3 covalent inhibitor-1
CAS :<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47G-631
CAS :<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Formule :C19H22F2N6O3Couleur et forme :SolidMasse moléculaire :420.41AJI-214
CAS :<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H13ClFN5OCouleur et forme :SolidMasse moléculaire :357.77NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Formule :C22H28N2O3Couleur et forme :SolidMasse moléculaire :368.47Aurora inhibitor 1
CAS :<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Formule :C23H25N9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :459.57LSD1-IN-35
CAS :<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Formule :C25H26N4O2SCouleur et forme :SolidMasse moléculaire :446.57SMARCA2/4-ligand-5
CAS :<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Formule :C20H13ClN4O3Couleur et forme :SolidMasse moléculaire :392.795DCHC
CAS :<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Formule :C15H8Cl2O3Couleur et forme :SolidMasse moléculaire :307.128TY-011
CAS :<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Formule :C18H16ClN5Couleur et forme :SolidMasse moléculaire :337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Formule :C18H18F2N6O3Couleur et forme :SolidMasse moléculaire :404.37PARP1-IN-29
CAS :<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Formule :C18H16FN3O2Couleur et forme :SolidMasse moléculaire :325.34Menin-MLL inhibitor 4
CAS :<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Formule :C32H38FN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :587.69AMI-408
CAS :<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Formule :C20H13Cl2N6NaO5SCouleur et forme :SolidMasse moléculaire :543.32KAT6A-IN-2
CAS :<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Formule :C23H29N5O5SCouleur et forme :SolidMasse moléculaire :487.57KAT6A-IN-1
CAS :<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Formule :C23H27N5O5SCouleur et forme :SolidMasse moléculaire :485.56HLCL-61
CAS :<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Formule :C23H24N2OCouleur et forme :SolidMasse moléculaire :344.45Bromodomain inhibitor-13
CAS :<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.43CP-352664
CAS :<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36SMARCA2-IN-2
CAS :<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Formule :C16H17N3Couleur et forme :SolidMasse moléculaire :251.33AJI-100
CAS :<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32
